Compare UNFI & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNFI | SRPT |
|---|---|---|
| Founded | 1976 | 1980 |
| Country | United States | United States |
| Employees | 25600 | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | 1996 | 2000 |
| Metric | UNFI | SRPT |
|---|---|---|
| Price | $45.98 | $20.09 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 7 | 28 |
| Target Price | ★ $44.71 | $25.40 |
| AVG Volume (30 Days) | 754.7K | ★ 3.2M |
| Earning Date | 03-10-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | $0.46 | N/A |
| Revenue Next Year | $2.18 | N/A |
| P/E Ratio | $183.88 | ★ N/A |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $21.27 | $10.42 |
| 52 Week High | $47.59 | $65.69 |
| Indicator | UNFI | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 66.09 | 56.96 |
| Support Level | $35.20 | $16.38 |
| Resistance Level | N/A | $23.01 |
| Average True Range (ATR) | 1.60 | 1.19 |
| MACD | 0.59 | 0.54 |
| Stochastic Oscillator | 70.86 | 51.65 |
United Natural Foods Inc is a wholesale distributor of natural, organic and specialty foods and nonfood products across North America. The company's products consist of national, regional and private label brands grouped into grocery and general merchandise, produce, perishables and frozen foods, nutritional supplements and sports nutrition, bulk and foodservice products, and personal care items. United Natural Foods serves various retail formats including conventional supermarket chains, natural product superstores, independent retail operators and foodservice channels such as e-commerce platforms. The company's operations are comprised of principal divisions: the wholesale division; the retail division; and other.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.